10-Q: Venus Concept Inc. Reports Q1 2025 Results: Revenue Declines Amid Strategic Review and Economic Headwinds

Venus Concept Inc.'s Q1 2025 revenue decreased by 21.9% year-over-year to $13.6 million, impacted by tighter credit markets, strategic shifts, and economic uncertainty.

Summary

• Venus Concept Inc. reported a net loss of $12.4 million for Q1 2025, compared to a net loss of $9.8 million in Q1 2024.
• Revenue for Q1 2025 was $13.6 million, a decrease of 21.9% from $17.5 million in Q1 2024.
• The company's performance was affected by tighter credit markets, strategic decisions to exit unprofitable markets, and overall economic uncertainty.
• The company is undergoing a strategic review to maximize shareholder value.
• As of March 31, 2025, cash and cash equivalents totaled $3.2 million.
• The company is working to mitigate supply chain issues and inflationary pressures.
• The company is managing foreign currency exposures but remains subject to volatility.
• The company is focused on improving credit screening practices to reduce bad debt expenses.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to declining revenue, increased net losses, and ongoing economic uncertainties. While the company is taking steps to mitigate risks and improve its financial position, the overall tone is pessimistic.

Positives

• The company is actively working to mitigate supply chain issues and inflationary pressures.
• The company is focused on improving credit screening practices to reduce bad debt expenses.
• The company is taking steps to exit countries which it does not believe will produce sustainable results.
• The Federal Reserve Board (Fed), the Bank of England, the European Central Bank, the Swiss National Bank and the Bank of Canada all recently reduced interest rates in an effort to reduce the degree of restrictiveness in monetary policy.

Negatives

• Q1 2025 revenue decreased by 21.9% to $13.6 million compared to $17.5 million in Q1 2024.
• Net loss for Q1 2025 was $12.4 million, compared to a net loss of $9.8 million in Q1 2024.
• Adjusted EBITDA loss was $8.3 million for Q1 2025, compared to $5.1 million for Q1 2024.
• The company delivered 196 systems in Q1 2025, compared to 314 systems in Q1 2024.
• Cash used in operating activities during the three months ended March 31, 2025 was $6.3 million, representing a $3.4 million increase compared to the three months ended March 31, 2024.

Risks

• The company's dependency on internal lease programs exposes it to customer credit risk.
• Customers may fail to make payments under their subscription or Venus Prime agreements.
• Customers may face difficulty securing third-party financing due to tightened credit markets and higher interest rates.
• The company needs to obtain, maintain, and enforce its intellectual property rights.
• Extensive governmental regulation and oversight in operating countries requires compliance.
• Systems may cause or contribute to adverse medical events, harming reputation and financials.
• A significant portion of operations are located in Israel, subject to political, economic, and military risks.
• The company's ability to remain in compliance with Nasdaq Capital Market listing requirements is uncertain.
• The company is dependent on one major contract manufacturer in Israel, exposing it to supply disruptions.
• The company relies on the expertise and retention of management.
• The company's ability to access capital markets and obtain credit on favorable terms is uncertain.
• The company faces risks from inflation, currency fluctuations, and currency exchange rates.
• Global supply disruptions and economic and political conditions pose uncertainties.
• The Israel-Hamas conflict may adversely affect operations and limit the ability to manage and market products.

Future Outlook

The company anticipates some supply challenges during the balance of 2025, due to geopolitical disruption in the middle east impacting shipping lanes, deliveries of materials and component parts, impacting production lead times that may impact our ability to manufacture the number of systems required to meet customer demand.

Management Comments

• The bulk of the first quarter revenue decline was due to a significant tightening in credit markets in the U.S. and international markets due to higher interest rates and economic uncertainty impacting our customers' ability and/or desire to secure capital equipment financing.
• In addition, our international results were negatively affected by our international strategy to wind down underperforming countries as we continued to transition to third party distributors.
• We remain focused on adapting to the challenges presented by the current macro-economic environment, as well as the opportunities presented by an easing of monetary policy.

Industry Context

The medical aesthetics industry is subject to economic cycles and consumer spending patterns. The report indicates a tightening of credit markets and economic uncertainty, which are impacting customers' ability to finance capital equipment purchases. This suggests a broader trend affecting capital equipment sales within the industry.

Comparison to Industry Standards

• It is difficult to compare Venus Concept's results directly to industry standards without specific competitor data.
• However, companies like Cynosure, Cutera, and Candela are key players in the medical aesthetics market.
• These companies' performance metrics, such as revenue growth, gross margins, and EBITDA, could serve as benchmarks.
• For example, if Cynosure reported stable revenue and positive EBITDA during the same period, it would suggest that Venus Concept's underperformance is company-specific rather than industry-wide.
• Similarly, comparing Venus Concept's gross margin of 64.2% to the industry average would provide insights into its operational efficiency.
• Given the company's strategic review, it is also relevant to compare its financial restructuring activities to those of other companies in similar situations.

Stakeholder Impact

• Shareholders face uncertainty due to the company's strategic review and financial performance.
• Employees may be affected by cost-cutting measures and restructuring activities.
• Customers may experience changes in product availability and financing options.
• Suppliers may be impacted by changes in the company's supply chain and manufacturing operations.
• Creditors face increased risk due to the company's financial challenges and debt obligations.

Next Steps

• The company will continue to evaluate its profitability and growth prospects in various countries.
• The company will continue to take steps to exit countries which it does not believe will produce sustainable results.
• The company will continue to focus on adapting to the challenges presented by the current macro-economic environment, as well as the opportunities presented by an easing of monetary policy.
• The company will continue to work with its suppliers and third-party manufacturers to mitigate supply issues and build inventory of key component parts.
• The company will continue to mitigate inflationary pressures, where possible, through price increases and margin management.
• The company will remain fully focused on its revised credit screening practices with the goal of reducing bad debt expenses.

Key Dates

Keywords

Venus Concept, financial results, Q1 2025, revenue, net loss, EBITDA, medical aesthetics, hair restoration, strategic review, credit markets, Israel, Madryn, EW Healthcare, Lincoln Park, convertible notes, reverse stock split